Vasculature News and Research

RSS

FDA approves Medtronic's Resolute Integrity DES to treat CAD

Advancing the clinical practice of interventional cardiovascular medicine, Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of the Resolute Integrity Drug-Eluting Stent (DES) for the treatment of coronary artery disease.

From Medtronic 17 Feb 2012

Scientists create first 3-D living tissue model of glioma

Brown University scientists have created the first three-dimensional living tissue model, complete with surrounding blood vessels, to analyze the effectiveness of therapeutics to combat brain tumors. The 3-D model gives medical researchers more and better information than Petri dish tissue cultures.

17 Feb 2012

Healthy lung tissue transplantation shows promise for patients with pulmonary diseases

For patients suffering from severe pulmonary diseases including emphysema, lung cancer or fibrosis, transplantation of healthy lung tissue may offer the best chance for survival. The surgical procedure, however, faces two primary challenges: an acute shortage of donor lungs and rejection of transplanted tissue by the recipient's immune system.

2 Feb 2012

Ikaria receives FDA orphan drug designation for use of iNO in PAH

Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the use of inhaled nitric oxide (iNO) with the INOpulse DS drug-delivery system as a combination product for pulmonary arterial hypertension.

23 Jan 2012

Study compares adoptive T-cell therapy with drug-based cancer treatment

In the treatment of large tumors, how effective is adoptive T cell therapy in comparison to drug-based cancer treatment? To answer this question, Dr. Kathleen Anders and Professor Thomas Blankenstein of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch and researchers of the Beckman Research Institute of the City of Hope Cancer Center in Duarte, California, USA designed and carried out a study comparing the two methods. Based on a mouse cancer model, the researchers elucidated the mechanisms of the two different treatments.

18 Jan 2012

Silence completes siRNA research work with AstraZeneca, MedImmune

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, announces the successful completion of its research work under the Research Collaboration and Delivery Collaboration with its partner AstraZeneca and its biologics arm, MedImmune.

7 Jan 2012

Boston Scientific introduces Charger PTA Balloon Catheter in the U.S.

Boston Scientific Corporation announces the U.S. launch of its Charger PTA Balloon Catheter, a 0.035" percutaneous transluminal angioplasty (PTA) balloon catheter designed for a wide range of peripheral angioplasty procedures.

13 Dec 2011

Akebia commences dosing in AKB-9778 Phase 1 study for diabetic macular edema and retinopathy

Akebia Therapeutics, Inc., a small molecule discovery and development company focused on anemia and vascular disorders, today announced that it has dosed the first subjects in a first-in-man Phase 1 study of AKB-9778, a first-in-class human protein tyrosine phosphatase beta (HPTPβ) inhibitor in development for diabetic macular edema (DME) and diabetic retinopathy (DR).

21 Nov 2011

Prox1 gene plays a critical role in formation and maintenance of lymphatic system

A century after the valves that link the lymphatic and blood systems were first described, St. Jude Children's Research Hospital scientists have detailed how those valves form and identified a gene that is critical to the process.

15 Nov 2011

Svelte initiates Rapamycin-eluting stent with bio-Eroding Carrier Technology implantation study

Svelte Medical Systems today announced treatment of the first patient in the DIRECT (Direct-on-a-wire Implantation of Rapamycin-eluting stent with bio-Eroding Carrier Technology) study at Auckland City Hospital in Auckland, New Zealand.

9 Nov 2011

DSM and Svelte Medical Systems enter into license and supply agreement

DSM, and Svelte® Medical Systems, Inc., a privately held company developing next generation endovascular therapies, today announced they have entered into a license and supply agreement granting Svelte the right to use DSM’s proprietary bioerodible amino acid based drug carrier in the design of their All In One non-thrombogenic, non-inflammatory drug-eluting stent system.

7 Nov 2011

New technologies could aid in malignant melanoma diagnosis and therapy

Because the incidence of malignant melanoma is rising faster than any other cancer in the U.S., researchers at Moffitt Cancer Center in Tampa, Fla., and colleagues at Tampa-based Intezyne Technologies, Inc., Western Carolina University and the University of Arizona are working overtime to develop new technologies to aid in both malignant melanoma diagnosis and therapy.

4 Nov 2011

Role of cardiovascular magnetic resonance in clinical cardiology

Cardiovascular Magnetic Resonance (CMR) has undergone substantial development and offers important advantages compared with other well-established imaging modalities.

3 Nov 2011

Christie introduces hand-held version of VeinViewer

Christie Medical Holdings, Inc. today announced the market launch of the company's newest product, VeinViewer Flex. With the addition of this fifth-generation VeinViewer, following the recent launch of VeinViewer VisionXTND, Christie now provides a full portfolio of three product tiers that addresses the needs of every major health care market segment.

18 Oct 2011

New insight into how emphysema and COPD develop

By studying mice exposed to tobacco smoke for a period of months, researchers have new insight into how emphysema and chronic obstructive pulmonary disease (COPD) develop.

14 Oct 2011

Narrow band imaging an equally effective alternative to chromoendoscopy for dysplasia

A new study from Spain finds that narrow band imaging appears to be a less time-consuming and equally effective alternative to chromoendoscopy for the detection of dysplasia (abnormal growths) in patients with long-standing inflammatory bowel disease.

13 Oct 2011

Preclinical studies shows EmPAC more effective than Taxol

Cornerstone Pharmaceuticals, Inc. has announced the publication of data from preclinical studies on EmPAC™, its nanoparticle reformulation of paclitaxel, in the August issue of the Journal of Nanoscience and Nanotechnology. The publication highlights data demonstrating improved safety and efficacy of EmPAC™ versus Taxol®, the generic formulation of paclitaxel and one of the most widely prescribed chemotherapies. EmPAC™ is a nanoemulsion formulation of Paclitaxel and is the lead product candidate of Cornerstone’s proprietary Emulsiphan™ cancer selective delivery nanotechnology platform. Taxol®, an injectable formulation of Paclitaxel, is currently used to treat a variety of cancers, including ovarian carcinomas, breast cancer, non-small cell lung cancer, and AIDS-related Kaposi’s sarcoma.

19 Sep 2011

Boston Scientific introduces Coyote Balloon Catheter for peripheral angioplasty

Boston Scientific Corporation has launched its Coyote Balloon Catheter, a highly deliverable and ultra-low profile 0.014 inch balloon dilatation catheter designed to treat patients undergoing peripheral angioplasty procedures below the knee. The Company has begun marketing the product in the U.S., Europe and other international markets.

19 Sep 2011

Semaphorin-PlexinD1 signaling pathway shows promise as therapeutic target for cancer treatment

In a new study published in the August 16th issue of Developmental Cell, researchers at NYU Langone Medical Center identified a molecular mechanism that guarantees that new blood vessels form in the right place and with the proper abundance.

17 Aug 2011

Mathematical model predicts progress of tumors from early stages to metastasis

Researchers from the University of Miami (UM) and the University of Heidelberg in Germany have developed a mathematical model to understand and predict the progress of a tumor, from its early stages to metastasis, in hopes of creating highly personalized treatment strategies for patients who have cancer. The findings are published in Nature's new online journal Scientific Reports.

1 Aug 2011